Equine Encephalosis Virus

Overview and Taxonomy of Equine Encephalosis Virus

Equine encephalosis virus (EEV) represents a significant, yet historically neglected, member of the Orbivirus genus within the family Sedoreoviridae [1]. The virus is the etiological agent of equine encephalosis (EE), a non-contagious, arthropod-borne febrile disease affecting equids [2]. The taxonomic placement of EEV is critical for understanding its biological behavior, evolutionary relationships, and the diagnostic challenges it presents, as it shares a striking degree of structural and epidemiological similarity with two of the most economically impactful orbiviruses: African horse sickness virus (AHSV) and bluetongue virus (BTV) [1, 12, 13]. This close phylogenetic kinship necessitates a sophisticated grasp of EEV's taxonomic position to differentiate it from these pathogens, a task of paramount importance given that EEV infection can clinically mimic AHSV, which carries a case-fatality rate of up to 95% in naïve horses and is a notifiable disease to the World Organisation for Animal Health (WOAH) [12, 15, 18].

Taxonomic Classification and Virion Structure

According to the International Committee on Taxonomy of Viruses (ICTV), EEV is classified within the genus Orbivirus, subfamily Sedoreovirinae, family Sedoreoviridae (formerly part of the Reoviridae family) [1, 12]. This taxonomic grouping is defined by a distinctive architectural feature: the virus possesses a complex, non-enveloped, icosahedral capsid composed of multiple concentric protein layers. The genome consists of ten linear segments of double-stranded RNA (dsRNA), which encode seven structural proteins (four major: VP1-3, VP5, VP7; and three minor: VP4, VP6, VP? depending on nomenclature) and five non-structural proteins (NS1, NS2, NS3, NS3a, NS4) [15]. The outer capsid is composed primarily of proteins VP2 and VP5, which are the targets of neutralizing antibodies and determine serotype specificity [3, 17]. The inner capsid layer is dominated by VP7, a highly conserved protein that serves as the serogroup-specific antigen and is the basis for diagnostic assays such as the competitive ELISA used for serological surveillance [10, 14]. This structural conservation of VP7 is a defining feature of the Orbivirus genus; indeed, monoclonal antibodies raised against AHSV VP7 have been shown to be serogroup-specific and do not cross-react with EEV, confirming their distinct serogroup identity despite their shared ancestry [14].

Serotype Diversity and Evolutionary Dynamics

Within the EEV serogroup, seven distinct serotypes have been definitively identified to date, designated EEV-1 through EEV-7 [2, 9]. These serotypes are classified based on the antigenic variability of the outer capsid protein VP2, which is encoded by genome segment 2 [3, 8]. Serotyping is not merely a taxonomic exercise; it has profound epidemiological and diagnostic implications. Serological surveys in South Africa using serum neutralization tests have demonstrated that serotypes 1 and 6 are the most frequently and extensively identified in horse populations, while serotypes 2, 3, 4, 5, and 7 occur more as sporadic, localized infections [9]. This differential distribution suggests varying fitness, transmissibility, or host immune responses across serotypes. Furthermore, the segmented nature of the EEV genome permits genetic reassortment, a phenomenon well-documented among orbiviruses. Whole-genome sequencing of field isolates from South Africa between 2010 and 2017 revealed widespread reassortment among the seven serotypes, with serotypes 1 and 4 being predominant in that period [3]. This capacity for reassortment is a powerful evolutionary driver, potentially allowing the virus to rapidly alter its antigenic profile, virulence, or vector competence, complicating both vaccine development and diagnostic interpretation.

Historical Context and Expanding Geographic Range

For over 40 years following its initial isolation from a horse in South Africa in 1967, EEV was believed to be a pathogen confined to southern Africa [2, 7]. This paradigm was shattered during 2008–2009, when EEV was isolated from horses during a febrile outbreak in Israel [8]. Critically, retrospective serological analysis revealed that EEV had actually been circulating in Israel since at least 2001, indicating that the virus had already established endemicity long before its clinical recognition [7]. Phylogenetic analysis of the Israeli isolates from this outbreak showed that segment 10 formed a novel genetic cluster and that segment 2 had approximately 92% sequence identity to the reference EEV-3 strain, suggesting a unique evolutionary lineage distinct from known South African strains [8]. This was not an isolated event; the geographic expansion continued. In 2008, EEV was isolated from a sick horse in India, confirmed through next-generation sequencing, marking the first definitive detection of the virus in Asia [4]. The presence of multiple competent Culicoides species in India, coupled with a seroprevalence of nearly 20% for Japanese encephalitis virus in the equine population of the region, underscores the potential for EEV to interact with other circulating arboviruses [4, 19]. Subsequent serological studies have confirmed EEV exposure in Palestine (48.5% seroprevalence), Jordan (2% seroprevalence), and Zimbabwe (63% seroprevalence in horses), painting a picture of a virus that is now recognized as endemic across southern Africa, the Middle East, and parts of Asia [6, 10]. The emergence of EEV outside of Africa is a stark demonstration of how a neglected pathogen can expand into new ecological niches, a phenomenon with direct parallels to the emergence of West Nile virus in the Americas and the northward expansion of bluetongue virus into Europe [2, 13].

Epidemiological and Ecological Niche

The geographic expansion of EEV is inextricably linked to its vector biology. The virus is transmitted exclusively by hematophagous biting midges of the genus Culicoides, primarily Culicoides imicola in the Old World [1, 16, 18]. This vector-dependent transmission imposes a strict seasonality on EEV incidence, with cases in South Africa and Zimbabwe peaking sharply from February to April (late summer and autumn), coinciding with periods of high vector abundance following seasonal rains [1, 10]. The virus's ecology is therefore highly sensitive to climatic and weather variables. While some models posit that climate is a crucial factor in determining the geographical distribution of Culicoides-borne viruses [5], other analyses suggest that herd immunity and specific weather fluctuations, such as extremely dry springs followed by rains, may be more potent drivers of local outbreak risk than broad climatic zones [5]. This complex interplay was demonstrated in Israel, where seroprevalence fluctuated significantly between years and across different climatic regions, with infection rates at individual farms showing a negative association with prior seroprevalence, indicative of herd immunity dynamics [5]. The risk of further expansion into Europe is not hypothetical; stochastic spatiotemporal modeling has determined that the probability of EEV entry into a country like France is substantially higher than that of AHSV, primarily through the importation of viremic horses [11]. This finding carries significant regulatory weight, as it suggests that EEV could serve as a sentinel for the potential invasion of more pathogenic orbiviruses, including AHSV, into the continent [11]. The recent detection of EEV in biting midges in South Africa, alongside zoonotic pathogens, further highlights the role of these vectors in a complex arbovirus transmission network [16]. Understanding the taxonomy and ecology of EEV is therefore not just an academic pursuit; it is a fundamental component of global animal health surveillance and risk assessment for emerging infectious diseases.

Molecular Pathogenesis and Viral Replication of EEV

Equine encephalosis virus (EEV) is a member of the genus Orbivirus within the family Sedoreoviridae, a taxonomic reclassification that underscores its phylogenetic and structural kinship with other economically significant arthropod-borne viruses such as African horse sickness virus (AHSV), bluetongue virus (BTV), and epizootic hemorrhagic disease virus (EHDV) [2, 12, 13]. The molecular pathogenesis of EEV is inextricably linked to its double-stranded RNA (dsRNA) genome architecture, the orchestrated expression of its structural and non-structural proteins, and the specific interactions it establishes with the equine host's cellular machinery. Understanding these molecular events at a granular level is critical, not only for deciphering the clinical spectrum of equine encephalosis, ranging from subclinical infection to pyrexia, thrombocytopenia, and lymphopenia [1], but also for informing risk assessments regarding the virus's potential to emerge in naive populations across Europe and the Middle East [11, 13].

Genomic Architecture and Virion Structure

The EEV genome comprises ten discrete segments of linear dsRNA, each encoding one or more proteins. These segments are encapsidated within a complex, icosahedral virion that exhibits the characteristic double-capsid structure of orbiviruses. The outer capsid is composed primarily of two proteins, VP2 and VP5, which are the principal determinants of serotype specificity and are responsible for receptor binding and membrane penetration during the initial stages of infection [2, 3]. The inner capsid, or core, is a highly stable structure built from VP3 (the subcore scaffolding protein) and VP7 (the major core surface protein), which together enclose the genomic RNA along with the enzymatic components required for transcription and capping [12]. The minor structural proteins, VP1 (RNA-dependent RNA polymerase), VP4 (capping enzyme), and VP6 (helicase/ATPase), are also housed within this core particle. The ability of the core particle to remain transcriptionally active within the host cytoplasm is a defining feature of orbivirus replication.

Viral Entry and Uncoating

The molecular pathogenesis of EEV begins with the interaction of the outer capsid protein VP2 with an as-yet-unidentified receptor(s) on the surface of susceptible equine cells. Given the tropism of EEV for endothelial cells and mononuclear phagocytes, evidenced by the clinicopathological hallmarks of thrombocytopenia and lymphopenia [1], it is plausible that the virus utilizes receptors expressed on these cell types, potentially including integrins or lectins analogous to those employed by BTV. Following receptor-mediated endocytosis, the acidic environment of the late endosome triggers a conformational change in VP2, leading to its dissociation and the exposure of VP5. This membrane penetration protein facilitates the release of the transcriptionally-competent core particle into the cytoplasm. This pH-dependent uncoating mechanism is a conserved feature of orbiviruses and is critical for establishing a productive infection.

Replication Strategy and Inclusion Body Formation

Once liberated into the cytoplasm, the EEV core particle functions as a molecular machine, utilizing its endogenous RNA-dependent RNA polymerase (VP1) to transcribe the ten dsRNA genome segments into positive-sense, capped, but non-polyadenylated mRNAs. This primary transcription occurs entirely within the core particle, protecting the nascent viral transcripts from host cell antiviral sensors that would otherwise recognize dsRNA. The newly synthesized viral mRNAs are then extruded into the cytoplasm, where they are efficiently translated by the host cell's ribosomes. Viral protein synthesis is essential for the formation of viral inclusion bodies (VIBs), which are discrete, granular structures within the cytoplasm that serve as the sites of viral replication and assembly. The non-structural protein NS2 is a key component of VIBs, acting as a scaffold to recruit viral RNA and structural proteins. NS3, another non-structural protein, plays a pivotal role in the later stages of infection by mediating the egress of progeny virions. Specifically, NS3 interacts with the cellular exocytic pathway and facilitates the budding of mature virus particles from the plasma membrane, often at sites of cellular stress [2, 12]. This non-lytic release mechanism allows the virus to spread efficiently while potentially avoiding some aspects of the host innate immune response.

Molecular Basis of Cellular and Host Tropism

The pathogenesis of EEV is most clearly manifested in the vasculature and the hematopoietic system. The profound lymphopenia and thrombocytopenia observed in naturally infected horses are not merely coincidental but are direct consequences of viral replication within these cell lineages [1]. The virus is believed to infect and replicate within endothelial cells lining small blood vessels, leading to increased vascular permeability and contributing to the pyrexia and, in some cases, icterus reported in clinical cases [3]. Endothelial infection may also trigger the activation of the coagulation cascade and platelet consumption, providing a mechanistic basis for the observed thrombocytopenia. Concurrently, EEV exhibits a marked tropism for lymphocytes and monocytes. The rapid depletion of lymphocytes from the peripheral blood is a characteristic finding, reflecting either direct viral lysis of infected cells or the induction of apoptotic pathways. The peak of leukopenia and thrombocytopenia within 24 hours of presentation [1] underscores the swift and aggressive nature of viral replication during the acute febrile phase of the disease.

Genetic Diversity, Reassortment, and Serotype Dynamics

A critical aspect of EEV molecular pathogenesis is the role of genetic reassortment in generating phenotypic diversity. Because orbiviruses possess segmented genomes, co-infection of a single host (or vector) with two different EEV serotypes can result in the emergence of novel progeny viruses containing a mixture of genome segments from both parental strains. Genomic surveillance in South Africa has demonstrated that reassortment is a frequent and widespread phenomenon among EEV field isolates, with serotype 1 and serotype 4 strains showing evidence of frequent genomic exchange [3]. This genetic plasticity has profound implications for viral fitness, antigenic variation, and potentially for the emergence of strains with altered virulence or transmissibility. The outer capsid protein VP2, the target of neutralizing antibodies, is under the most significant selective pressure from the host immune response, and reassortment allows the virus to rapidly explore new antigenic landscapes. The presence of seven distinct serotypes (EEV-1 through EEV-7) circulating both endemically and emerging in new geographic regions, such as Israel and India, is a testament to this evolutionary capacity [2, 4, 7, 8].

Host Immune Evasion and Inflammatory Response

While the molecular details of EEV's evasion of the equine innate immune system are less well characterized than for AHSV or BTV, several general mechanisms can be inferred. The use of a dsRNA genome and the sequestration of the genome within a stable core particle are themselves fundamental evasion strategies that limit detection by cytoplasmic pattern recognition receptors such as RIG-I and MDA-5. The non-structural protein NS3 is also thought to play a role in counteracting host interferon responses, analogous to its function in other orbiviruses. The acute clinical signs of pyrexia, tachypnoea, and tachycardia [1] are driven by the host's inflammatory response to viral replication. The release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interferons from infected endothelial cells and leukocytes contributes to systemic inflammation and the febrile response. In severe cases, this dysregulated inflammatory cascade can lead to vascular leakage, tissue edema, and the multi-organ dysfunction that, albeit rarely, can result in mortality. The pattern of neurological signs that are occasionally observed, though reported to be inversely associated with EEV infection compared to other causes of encephalitis, such as West Nile virus [3], likely results from secondary effects of vascular injury and cytokine-mediated disruption of the blood-brain barrier rather than direct neuronal invasion.

Comparative Molecular Pathogenesis with Related Orbiviruses

The comparative analysis of EEV with its close relatives, AHSV and BTV, provides valuable insights into the determinants of host range and virulence. While AHSV is highly pathogenic in horses, causing mortality rates exceeding 90% in the pulmonary form [12, 15], EEV typically induces a self-limiting febrile illness with very low mortality [1, 2]. The molecular basis for this stark difference in virulence remains unknown but likely involves variations in the efficiency of replication in equine endothelial cells, the ability to suppress the host interferon response, and the capacity to induce systemic vascular leakage. Both viruses share the same Culicoides vectors [16, 18] and exhibit similar cellular tropisms, yet the clinical outcome is dramatically different. The EEV outer capsid proteins, particularly VP2 and VP5, may have a lower affinity for equine-specific entry receptors or may be more susceptible to neutralization by the equine immune system. Furthermore, the induction of a robust and rapid type I interferon response may restrict EEV replication more effectively than it does the replication of the hypervirulent AHSV strains. The spread of EEV from South Africa to Israel and India [4, 7, 8] serves as a crucial sentinel event, demonstrating that orbiviruses previously thought to be geographically restricted can indeed invade new ecological niches where competent vectors and susceptible hosts exist, raising the specter of a future incursion of AHSV along a similar pathway [11, 13].

Epidemiology, Vector Ecology, and Global Distribution

Historical Paradigm and the Southern African Epicenter

For over four decades following its initial isolation from a horse in South Africa in 1967, equine encephalosis virus (EEV) was erroneously considered a pathogen of exclusive relevance to the southern African subcontinent [1, 2]. This perception was rooted in the virus's endemic stability within the region, where a complex interplay of susceptible equid populations, competent Culicoides vector species, and permissive climatic conditions sustained continuous, largely subclinical circulation. The seminal work by Howell et al. [9] on Thoroughbred yearlings in South Africa between 1999 and 2004 provided the first rigorous, long-term serological surveillance data, revealing a dramatic annual fluctuation in serotype-specific antibody prevalence ranging from a mere 3.6% to 34.7%. This variability underscores the profoundly dynamic nature of EEV transmission, dictated by the seasonal abundance of its vectors and the immunological naivety of each annual cohort of foals. Critically, this study [9] demonstrated that serotypes 1 and 6 were dominant and widely disseminated across defined geographical regions, while serotypes 2, 3, 4, 5, and 7 appeared as sporadic, localized incursions affecting only individual animals within specific stud farms. This pattern of widespread serotype dominance punctuated by the focal emergence of minor serotypes suggests a complex, multi-strain ecosystem where herd immunity against prevalent serotypes creates transient ecological niches for rarer variants.

The epidemiological significance of the southern African endemic cycle is further illuminated by longitudinal studies in the Highveld region of Zimbabwe [10]. Here, sentinel herd surveillance employing competitive ELISA revealed a median EEV seroprevalence of 63% in horses and an astonishing 80% in donkeys. The seasonal sero-incidence, 10.5% in horses and 50% in donkeys, paints a stark picture of extremely high transmission pressure, particularly towards the end of the rainy season (March to May), a period coincident with peak Culicoides abundance [10]. The remarkably high seroprevalence in donkeys, coupled with their often asymptomatic carriage, positions them as potentially critical, underappreciated reservoir hosts, a role analogous to that of zebras for African horse sickness virus (AHSV). This observation has profound implications for disease control in resource-limited settings, where donkey populations are often large and unmonitored.

The Emergence Beyond Africa: A Retrospective Revelation

The long-held geographic dogma was shattered during 2008–2009, when a febrile outbreak in horses in Israel led to the isolation of EEV, marking the first confirmed incursion of the virus outside of Africa [2, 8]. Phylogenetic analysis of the Israeli isolates, particularly of genome segment 10, demonstrated they formed a novel cluster, while segment 2 exhibited approximately 92% sequence identity to the reference EEV serotype 3 (EEV-3) [8]. This genetic divergence, while clearly related to known African strains, suggested a period of independent evolution or a distinct origin that remained uncertain. The true magnitude of this epidemiological shift was only appreciated through meticulous retrospective serological analysis. Westcott et al. [7] demonstrated, through serum neutralization testing of archived equine sera collected for other diagnostic purposes, that EEV had been circulating undetected in Israel as early as 2001, with sero-incidence rates ranging from 20% to 100% between 2001 and 2008. This finding is a profound lesson in arbovirus emergence: a pathogen can establish and maintain transmission cycles within a naive ecosystem for years before clinical disease triggers recognition.

The subsequent spread of EEV within the Middle East has been carefully documented. A cross-sectional serosurvey involving 316 horses across 21 farms in Israel, 66 horses in Palestine, and 100 horses in Jordan revealed a stark gradient of exposure. Seroprevalence was 58.2% in Israel and 48.5% in Palestine, solidifying the virus's endemic status in the region [6]. In stark contrast, only 2% of horses in Jordan were seropositive, a statistically significant difference (P < 0.001) that suggests a recent or intermittent incursion into that country, possibly constrained by vector ecology or animal movement patterns [6]. Multivariable analysis identified the farm and horse age as significant risk factors, highlighting the local, farm-level nature of transmission and the cumulative probability of exposure over an animal's lifetime.

Expansion into South Asia: The Indian Incursion

The global reach of EEV was further extended by its detection in India. Using next-generation sequencing, a virus isolated from a sick horse in 2008 was definitively identified as EEV [4]. The presence of EEV in India is of considerable concern given the country's vast and dense equid population and the presence of multiple competent Culicoides vector species, which are pivotal for the virus's natural maintenance and transmission [4]. The Indian subcontinent, with its climatic diversity ranging from arid to tropical, provides a vast arena for potential EEV expansion. The isolation of EEV in India, along with the subsequent characterization of other novel reoviruses from ticks in the region [20], underscores the rich, underexplored arbovirus diversity and the potential for future emergence events facilitated by animal trade and climate change.

Vector Ecology: The Culicoides Nexus

The epidemiology of EEV is inextricably linked to the biology, distribution, and behavior of its primary vectors: biting midges of the genus Culicoides (Diptera: Ceratopogonidae) [1, 2, 12, 16]. Like its congeners AHSV and bluetongue virus (BTV), EEV is a non-contagious, arthropod-borne orbivirus whose transmission is entirely reliant on the bite of an infected midge. In South Africa, field studies have confirmed the role of Culicoides as vectors, with EEV detected in midge pools via RT-PCR, yielding a minimum infection rate (MIR) of 0.2 [16]. This detection, alongside other arboviruses like Shuni virus, underscores the vector's capacity to transmit a diverse array of pathogens.

The ecology of Culicoides is profoundly climate-dependent, a factor that governs the spatial and temporal distribution of EEV. Midge abundance, survival, and viral replication rates within the vector are all exquisitely sensitive to temperature, humidity, and rainfall. However, the relationship between climate and EEV transmission is not simplistic. A detailed analysis of the 2008 EEV outbreak in Israel revealed that exposure was not strictly climate-specific but was highly influenced by herd immunity and weather fluctuations [5]. Interestingly, the study identified an extremely dry period (significantly lower than average spring precipitation) preceding the 2008 outbreak, challenging the assumption that outbreaks are strictly tied to wet conditions [5]. This suggests that in arid regions, drought may concentrate vectors and hosts, facilitating transmission, or that herd immunity levels, shaped by prior years of exposure, are the more dominant driver of outbreak dynamics. The seroprevalence in Israel fluctuated annually and was found to be highest in different climatic regions during different years, reinforcing the idea that local herd immunity, rather than a static climate envelope, is the primary determinant of infection risk [5].

The threat of EEV's introduction into Europe has been rigorously assessed using stochastic spatiotemporal models. A comparative risk analysis for France, a country with a large and internationally connected equine population, found that the probability of EEV entry was substantially higher than that of the far more pathogenic AHSV [11]. The most likely entry route for EEV was identified as the importation of a live, viraemic horse, in contrast to AHSV, which was more likely to enter via an infected vector [11]. This distinction has critical implications for surveillance and biosecurity. The model demonstrated that the most effective measure to reduce the probability of EEV entry into France was the implementation of pre-import quarantine for horses from both EU and non-EU countries, rather than vector control measures on ships or aircraft [11]. This quantitative risk assessment provides a clear, evidence-based pathway for international regulatory bodies, including the World Organization for Animal Health (WOAH), to consider when evaluating the threat posed by EEV.

Global Distribution and the Threat of Climate-Driven Expansion

The current known geographic distribution of EEV spans southern Africa, the Middle East (Israel, Palestine, and Jordan), and South Asia (India) [1, 2, 4, 6]. Retrospective analysis has confirmed circulation in parts of central Africa, as evidenced by the high seroprevalence in donkeys and horses in Zimbabwe [10]. The potential for this distribution to expand is significant. The primary constraint is the global range of competent Culicoides vectors, particularly species like C. imicola, which are already expanding their range northwards into southern Europe [13, 18]. Global warming is a critical driver, as increased temperatures can accelerate viral replication within the vector (shortening the extrinsic incubation period), extend the vector's breeding season, and facilitate the survival of midge populations at higher latitudes [1, 13]. The emergence of BTV in northern Europe over the past two decades serves as a stark precedent and a sentinel event, demonstrating the capacity of Culicoides-borne orbiviruses to colonize new, temperate regions [13]. EEV, sharing the same transmission machinery, possesses the same potential.

The clinical consequences of this expansion cannot be overlooked. While EEV is typically associated with mild febrile illness, its clinical signs, pyrexia, tachycardia, tachypnoea, lymphopenia, and thrombocytopenia, are remarkably similar to those of notifiable diseases like AHS [1, 3]. In a study of naturally infected horses in South Africa, 48.1% of EEV-positive horses presented with neurological abnormalities, and coinfections with other viruses such as West Nile virus, Middelburg virus, and AHSV were common [3]. This diagnostic confusion can lead to misdiagnosis and delayed implementation of control measures for more dangerous pathogens. As EEV encroaches into new territories, it will become a differential diagnosis of primary importance, and its presence may signal the potential for the concurrent or subsequent emergence of AHSV, a disease with a case-fatality rate in horses exceeding 90% [2, 11, 12]. The global distribution of EEV, therefore, is not merely a geographic curiosity but a dynamic, evolving threat that serves as a barometer for the broader emergence of Culicoides-borne diseases in a rapidly warming world.

Clinical Manifestations and Clinicopathological Findings

Equine encephalosis virus (EEV) infection is characterized by a spectrum of clinical presentations, ranging from inapparent or subclinical infection to an acute febrile illness that, while rarely fatal, can mimic other notifiable equine diseases such as African horse sickness (AHS). The clinical phenotype of EEV is predominantly non-neurological, a somewhat paradoxical feature given the virus’s name. The clinical manifestations and associated clinicopathological abnormalities are now better defined by recent retrospective and prospective studies, which have supplanted earlier anecdotal accounts.

General Clinical Presentation and Vital Sign Alterations

The most consistent and universally reported clinical sign of EEV infection is pyrexia. In a comprehensive retrospective analysis of 25 naturally infected horses conducted at the Onderstepoort Veterinary Academic Hospital, pyrexia was documented in 100% of cases, with a mean maximum temperature of 39.3°C (standard deviation 0.86°C) [1]. This febrile response is typically biphasic in some cases and can persist for several days, often as the initial and sometimes only recognizable clinical abnormality. The presence of fever is so characteristic that it forms the cornerstone of field-based clinical suspicion, particularly when occurring in a seasonal pattern (late summer to autumn in southern Africa, corresponding to peak Culicoides vector activity) [1, 3].

Tachycardia and tachypnoea are also prominent findings. In the same cohort, tachycardia (heart rate > 44 beats per minute) was observed in 64% of horses, with a median maximum heart rate of 52/min (range 36–100/min) [1]. Tachypnoea (respiratory rate > 16 breaths per minute) affected 76% of horses, with a median maximum respiratory rate of 24/min (range 12–60/min) [1]. These elevations in heart and respiratory rates are likely multifactorial, driven directly by the systemic inflammatory response to viral infection and compounded by the metabolic demands of pyrexia and, in some cases, by dehydration or secondary pulmonary compromise. Importantly, the degree of tachycardia and tachypnoea in EEV is generally less severe than that observed in the acute pulmonary form of AHS, a critical distinguishing feature for clinicians in endemic regions [1, 3, 15].

Neurological manifestations and the “Encephalosis” Paradox

Despite the name “equine encephalosis,” which implies a primary encephalitic process, clinical neurological signs are neither a hallmark nor a frequent finding in naturally occurring EEV infections. Indeed, a large surveillance study in South Africa (2010–2017) involving 106 EEV-positive horses found that neurological signs were inversely associated with EEV infection (odds ratio < 1, p < 0.05) when compared to EEV-negative horses presenting with similar clinical syndromes [3]. This counterintuitive finding suggests that while EEV can be detected in horses with neurological disease, it is more commonly an incidental finding or a co-infecting agent rather than the primary cause of central nervous system (CNS) signs.

When neurological deficits do occur, they are typically subtle and non-specific. Depression, lethargy, and mild ataxia have been anecdotally reported, but these signs are often attributable to the systemic febrile illness rather than direct viral neuroinvasion. In the 2025 study by Piketh et al., neurological evaluation was not a primary focus, and no horses were specifically described as comatose or exhibiting seizure activity [1]. This is in stark contrast to other equine encephalitic viruses, such as West Nile virus (WNV) or Eastern equine encephalitis virus (EEEV), where frank encephalitis, cranial nerve deficits, and recumbency are common [23, 26, 27]. The pathophysiological basis for this divergence is likely related to the limited neurotropism of EEV compared to alphaviruses and flaviviruses. Experimental infection data, though limited, support the notion that EEV replication is largely restricted to lymphoid and vascular endothelial tissues, with the CNS being an infrequent target except in cases of severe systemic compromise or co-infection [2, 3].

The presence of other clinical signs, icterus (18.9%) and dyspnea (11.3%), has been documented in EEV-positive horses, though these are also relatively non-specific [3]. Icterus may reflect hepatic involvement or, more likely, hemolysis secondary to viral-induced vascular damage or immunemediated destruction, analogous to findings in other orbiviral infections. Dyspnea, when present, is usually mild and not the severe, frothy, pulmonary edema characteristic of peracute AHS [3, 15, 21].

Clinicopathological Abnormalities: Hematological and Biochemical Profiles

Hematological alterations are among the most valuable diagnostic clues for EEV, particularly in the acute phase of illness. The predominant findings reflect a viral-induced hematopoietic disturbance.

Leukopenia and Lymphopenia: Leukopenia (white blood cell count < 5.5 × 10⁹ cells/L) and absolute lymphopenia are consistently identified within the first 24 hours of clinical presentation. In the retrospective study, the median leukocyte count on presentation was 5.44 × 10⁹ cells/L (range 2.08–18.07 × 10⁹ cells/L), with a median lymphocyte count of 1.17 × 10⁹ cells/L (range 0.15–9.21 × 10⁹ cells/L) [1]. This leukopenic profile is characteristic of an acute viral infection and likely results from a combination of lymphocyte sequestration in lymphoid tissues, direct viral-induced lymphocytolysis (Orbiviruses can replicate in lymphocytes and macrophages), and a cytokine-mediated redistribution of white blood cells. The lymphopenia is transient, with cell counts often normalizing within a few days as the febrile phase resolves.

Thrombocytopenia: A striking and potentially more specific finding is thrombocytopenia. The median platelet count in the acute phase was 67.5 × 10⁹ cells/L (range 3–303 × 10⁹ cells/L), with severe thrombocytopenia (< 50 × 10⁹ cells/L) occurring in a substantial proportion of cases [1]. This degree of platelet reduction is more profound than what is typically seen in many other infectious fevers of horses, with the notable exception of equine infectious anemia (EIA), where thrombocytopenia is also a hallmark [24, 25]. The mechanism in EEV is likely multifactorial: direct viral damage to megakaryocytes, increased platelet consumption due to widespread vascular endothelial activation, and immune-mediated clearance. The presence of marked thrombocytopenia in a febrile horse should therefore raise strong suspicion for EEV in endemic areas.

Anemia and Icterus: While mild anemia can occur, it is not a dominant feature of acute EEV. The icterus observed in approximately 19% of cases [3] suggests subclinical hemolysis or hepatic dysfunction, though bilirubin fractionation (direct vs. indirect) has not been systematically reported in the literature. Serum biochemical abnormalities have not been extensively characterized, but mild to moderate elevations in liver enzymes (aspartate aminotransferase, gamma-glutamyl transferase) could be anticipated in icteric horses, reflecting hepatocellular injury or cholestasis.

Subclinical Infections and the Role of Maternal Immunity in Foals

EEV infection is frequently subclinical, particularly in endemic populations where prior exposure and maternal antibodies modulate disease expression. A landmark study on Thoroughbred foals in South Africa documented an EEV serotype 4 outbreak in which at least 94% of foals became infected, yet 41% of infected foals did not exhibit any detectable pyrexia [22]. This high rate of subclinical infection underscores the importance of serological surveillance for understanding true viral circulation. The presence of maternally derived neutralizing antibodies, 37% of foals had pre-existing antibodies to EEV-4, did not prevent infection but likely attenuated the clinical response [22]. This phenomenon has direct implications for clinical diagnosis: in young foals, the absence of fever does not exclude EEV infection, and reliance on pyrexia as a sole screening criterion will underestimate disease incidence.

Co-infections and Diagnostic Complexity

EEV does not exist in a microbiological vacuum, particularly in southern Africa where other orbiviruses (AHSV, bluetongue virus) and arboviruses (WNV, Middelburg virus) circulate concurrently. In the South African surveillance study, 17 of 106 EEV-positive horses had co-infections: 4.7% with WNV, 3.8% with Middelburg virus, and 7.6% with AHSV [3]. This high rate of co-infection complicates the attribution of specific clinical signs to EEV alone. For instance, nervous signs in a horse co-infected with EEV and WNV are far more likely to be attributable to WNV, which is a proven neuropathogen [23]. Clinicians must therefore interpret clinical manifestations with caution and pursue molecular testing for multiple pathogens when faced with a febrile or neurologically abnormal horse in an endemic region.

The World Organisation for Animal Health (WOAH) recognizes EEV as a differential diagnosis for AHS, and the clinicopathological findings, particularly the combination of pyrexia with leukopenia, lymphopenia, and thrombocytopenia, in the absence of severe neurological signs, provide a crucial framework for initial diagnostic triage. While EEV is not itself a WOAH-listed disease, its clinical overlap with AHS (a notifiable disease of significant economic consequence) mandates that any suspect case be subjected to specific virological testing to fulfill international reporting obligations [15, 21].

Diagnostic Approaches for Equine Encephalosis Virus

The diagnostic landscape for equine encephalosis virus (EEV) is multifaceted, reflecting the virus’s position as a neglected, endemic orbivirus with clinical presentations that can closely mimic those of far more pathogenic agents such as African horse sickness virus (AHSV). Accurate and timely diagnosis is not merely an academic exercise; it is a critical component of surveillance, outbreak response, and the safeguarding of international equine commerce. Given that EEV is a non-contagious, vector-borne disease whose clinical signs, pyrexia, tachycardia, tachypnoea, and occasional icterus, overlap significantly with other notifiable conditions, the diagnostic workup must be comprehensive, integrating clinical pathology, molecular detection, serological profiling, and, where necessary, virus isolation [1, 3]. The approaches outlined below draw heavily on the accumulated experience from endemic regions in Southern Africa and the Middle East, where EEV has been a recognized pathogen for decades, as well as from more recent incursions into novel ecological niches [2, 6].

Clinical Pathology and Haematological Profiling

A thorough haematological evaluation serves as the initial, and often highly informative, diagnostic gatekeeper. The seminal retrospective study by Piketh et al. (2025) on naturally infected horses provided a detailed characterization of the clinicopathological abnormalities observed within the first 24 hours of presentation [1]. A consistent triad of haematological perturbations was identified: leukopenia (median 5.44 × 10⁹ cells/L), lymphopenia (median 1.17 × 10⁹ cells/L), and, most notably, thrombocytopenia (median 67.5 × 10⁹ cells/L) [1]. The degree of thrombocytopenia observed in this cohort was profound, with a range extending as low as 3 × 10⁹ cells/L, suggesting a significant virus-induced consumption or sequestration of platelets, a finding that aligns with the pathogenesis of other closely related orbiviruses such as bluetongue virus (BTV) [1, 13]. While not pathognomonic, this constellation of findings, particularly the combination of fever with severe thrombocytopenia and lymphopenia in a horse from an endemic region during the late summer or autumn (February to April in the Southern Hemisphere), provides a strong clinical suspicion for EEV infection and helps differentiate it from other febrile illnesses [1]. It is critical to note, however, that these abnormalities may be transient or absent in subclinical infections or in horses sampled later in the disease course, as highlighted by the study's limitation of evaluating cases at differing post-infection time points [1]. Furthermore, a high proportion (48.1%) of EEV-positive horses in a South African study presented with neurological signs, albeit with a negative statistical association for EEV as the primary cause, underscoring the need to rule out concurrent infections or other aetiologies when neurological deficits are present [3].

Molecular Diagnostics: RT-PCR and Genomic Characterization

Molecular detection has become the cornerstone of definitive antemortem diagnosis, particularly given the challenges of rapid virus isolation in cell culture. The use of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays, including nested formats, has been extensively validated for the detection of EEV RNA in whole blood [3]. The study by Snyman et al. (2021), which screened 1,523 horses over an eight-year period, employed a nested rRT-PCR to identify 111 positive cases (7.3%) from animals presenting with febrile, respiratory, or neurological signs, as well as sudden death [3]. This approach offers high sensitivity and specificity, and the nested design can enhance detection limits even in samples with low viral loads, which is critical given that viraemia may be transient. The target gene for these assays is often segment 10, which encodes the non-structural protein NS3, or segment 2, encoding the outer capsid protein VP2, which is the primary determinant of serotype specificity [2, 8]. Subsequent phylogenetic analysis of amplified products allows not only for confirmation of EEV but also for serotype determination and the identification of reassortment events, which are known to occur frequently between the seven recognized EEV serotypes [3, 8]. For instance, analysis of VP2 sequences from South African isolates collected between 2010 and 2017 revealed serotypes 1 and 4 as predominant, with widespread reassortment of other genome segments [3]. When an outbreak occurred in Israel in 2008–2009, phylogenetic analysis of segment 10 formed a new cluster, while segment 2 showed ~92% sequence identity to EEV-3, demonstrating the power of molecular diagnostics to trace viral origins and movements [8]. Next-generation sequencing (NGS) has also proven invaluable for the discovery and characterization of EEV in novel regions, such as its identification from a sick horse in India in 2008, where traditional methods had failed [4, 20]. The World Organisation for Animal Health (WOAH) recognizes RT-PCR as a prescribed test for international movement for other orbiviruses, and its application for EEV should follow similar validation standards.

Serological Assays and Antibody Detection

Serological testing plays a pivotal role in epidemiological surveillance, retrospective diagnosis, and the assessment of herd immunity. The serum neutralization test (SNT) is considered the gold standard for detecting serotype-specific antibodies, as it measures functional neutralizing antibodies against the viral VP2 protein [6, 9]. The SNT, often performed using a constant virus-varying serum method in microtitre plates, has been instrumental in demonstrating the circulation of EEV in Israel since at least 2001, with retrospective analyses of stored sera showing seroprevalence rates ranging from 20-100% between 2001 and 2008 [7]. It was also the method of choice for the first seroprevalence surveys in Palestine (48.5%) and Jordan (2%), revealing a stark regional heterogeneity in exposure [6]. However, the SNT is labor-intensive, requires live virus and cell culture facilities, and can take several days to yield results, rendering it unsuitable for rapid outbreak response.

For broader, more throughput-efficient screening, the competitive enzyme-linked immunosorbent assay (cELISA) has been employed. These assays typically target the group-specific VP7 protein, which is highly conserved across all EEV serotypes [10, 17]. The cELISA format is advantageous as it can be used across multiple equid species (horses, donkeys, zebras) and is less affected by the species of the secondary antibody. In Zimbabwe, Aharonson-Raz et al. used a cELISA to demonstrate a high seroprevalence (63% in horses, 80% in donkeys) and sero-incidence (10.5% in horses, 50% in donkeys) over sequential rainy seasons [10]. It is important to recognize that serology cannot distinguish between recent infection and past exposure, and maternally derived antibodies in foals can confound interpretation in younger animals [22]. Furthermore, the timing of sample collection is critical; antibodies typically become detectable by 7-14 days post-infection, and a four-fold rise in titre between acute and convalescent sera (collected 14-21 days apart) is necessary for serological confirmation of active infection [22].

Virus Isolation and Antigen Detection

Virus isolation, while historically the definitive diagnostic standard, is rarely employed as a first-line approach due to its technical demands and time requirements. Isolation is typically performed by inoculating susceptible cell lines (e.g., BHK-21, Vero, or KC cells derived from Culicoides) with whole blood collected in anticoagulant (EDTA) from febrile horses [8, 20]. The presence of the virus is then confirmed by cytopathic effect (CPE), followed by serological identification or RT-PCR. In the Israeli outbreak, EEV was successfully isolated from clinical samples, enabling subsequent phylogenetic characterization [8]. However, isolation success rates can be low, particularly if samples are not handled properly or if the horse has already mounted a neutralizing antibody response. Antigen-capture ELISA (AC-ELISA) using monoclonal antibodies or phage-displayed single-chain variable fragments (scFvs) has been developed for related orbiviruses like AHSV, demonstrating the potential for serogroup-specific detection [14]. While such assays are not yet commercially available for EEV, the principle highlights a future avenue for rapid antigen detection directly from blood or tissue samples, bypassing the need for cell culture.

Differential Diagnosis and Integrated Testing Algorithm

Given that EEV can present with a spectrum of signs ranging from subclinical infection to severe febrile illness and sudden death, it must be included in the differential diagnosis for any febrile equid in endemic or at-risk regions. The most critical differentiation is from AHSV, which shares the same Culicoides vector and can present with similar pyrexia, oedema, and respiratory distress [11, 12, 15]. The case fatality rate for AHSV (up to 95% in naive horses) is vastly higher than that for EEV (typically less than 5%), making rapid rule-out of AHSV a top priority [12]. As such, a diagnostic algorithm for a febrile horse should prioritize testing for AHSV via antigen-capture ELISA or RT-PCR, followed by or concurrently with testing for EEV [15]. Other differentials include equine infectious anaemia (EIA), which can present with fever and thrombocytopenia but is detected via AGID or ELISA for antibodies against p26 or gp90 [24, 25]; equine herpesvirus-1 (EHV-1) myeloencephalopathy, which presents with neurological signs and is diagnosed via qPCR on nasal swabs and blood [28]; and vector-borne flaviviruses such as West Nile virus (WNV), which may require specific RT-PCR or IgM-capture ELISA on cerebrospinal fluid [23]. In recent years, novel viruses such as equine hepacivirus and equine parvovirus-hepatitis have also been identified, though their clinical presentation is more aligned with hepatic disease [29]. The increasing availability of syndromic multiplex PCR panels, which can simultaneously detect EEV, AHSV, WNV, and other arboviruses, represents a significant advance for diagnostic laboratories [3]. For imported horses, the pre-import testing protocol must consider the animal’s origin, vaccination history, and any history of pyrexia, with quarantining and testing for both EEV and AHSV recommended, particularly if the animal originates from or has transited through endemic zones [11].

Immunology, Prevention, and Control Strategies

Immunological Basis of Equine Encephalosis Virus Infection

The host immune response to Equine Encephalosis Virus (EEV) is a critical determinant of clinical outcome and epidemiological persistence, yet the specific immunological mechanisms remain less characterized than those of other orbiviruses such as African horse sickness virus (AHSV) or bluetongue virus (BTV). EEV, a member of the Orbivirus genus within the Sedoreoviridae family [1, 2], induces a humoral immune response that is both serogroup- and serotype-specific. The virus possesses a ten-segmented double-stranded RNA genome encoding seven structural proteins, including the outer capsid protein VP2, which is the primary determinant of serotype specificity and the principal target of neutralizing antibodies [3, 8]. Phylogenetic analyses of the outer capsid protein VP2 have identified seven distinct EEV serotypes (EEV-1 through EEV-7), each capable of eliciting a serotype-restricted neutralizing antibody response. This serotypic diversity poses a substantial challenge to the development of broadly protective vaccines, as immunity acquired from natural infection with one serotype does not necessarily confer protection against heterologous serotypes [3, 9]. Retrospective serological surveys conducted in South Africa from 1999 to 2004 revealed that individual yearlings could experience sequential or concurrent infections with multiple serotypes, with serotypes 1 and 6 being the most prevalent, while serotypes 2, 3, 4, 5, and 7 were detected sporadically and locally [9]. This pattern indicates that the equine population in endemic regions is repeatedly exposed to antigenically diverse strains, necessitating a continuously adaptive immune response.

The innate immune response to EEV infection is characterized by a pronounced but transient leukopenia, lymphopenia, and thrombocytopenia, as documented in a recent retrospective analysis of naturally infected horses in South Africa [1]. Within 24 hours of presentation, affected horses exhibited median lymphocyte counts of 1.17 × 10⁹ cells/L and median platelet counts of 67.5 × 10⁹ cells/L, indicating virus-induced immune cell depletion or sequestration [1]. This hematological profile mirrors that observed in other orbiviral infections, including AHSV and BTV, and suggests that EEV may directly target or modulate lymphoid and megakaryocytic lineages during the acute febrile phase [1, 12]. The presence of pyrexia (100% of cases), tachycardia (64%), and tachypnoea (76%) in naturally infected horses further underscores the systemic inflammatory response triggered by viral replication [1]. The clinical significance of these immune alterations is that they may predispose infected animals to secondary infections or exacerbate clinical disease, particularly in young or immunologically naïve populations such as foals [1, 22].

Maternally derived antibodies play a crucial role in protecting foals during their first season of exposure to EEV. In a detailed study of Thoroughbred foals on a South African stud farm, 37% of foals possessed maternal antibodies against EEV-4 prior to an autumn outbreak, yet despite this pre-existing immunity, a cumulative infection incidence of at least 94% was observed among the foal cohort [22]. Remarkably, 41% of infected foals demonstrated no detectable pyretic episode, suggesting that maternal antibodies partially mitigated clinical expression but did not prevent infection [22]. This finding underscores the limitations of passive immunity in completely blocking orbiviral transmission and highlights the importance of active immunization to establish robust, long-lasting protective immunity. Furthermore, the study revealed that pyrexia monitoring alone is an insufficient surveillance tool for detecting EEV infection in foals, as a substantial proportion of infected animals remained afebrile [22]. This has significant implications for outbreak detection and control, as reliance solely on clinical signs may lead to underestimation of viral circulation within a herd.

The role of cell-mediated immunity in EEV infection remains poorly defined, but extrapolations from related orbiviruses, particularly BTV, suggest that cytotoxic T lymphocytes (CTLs) targeting conserved internal viral proteins (e.g., VP7) may contribute to viral clearance and cross-serotype protection [14, 17]. The serogroup-specific detection of AHSV using phage-displayed chicken single-chain variable fragments (scFvs) that do not cross-react with EEV indicates that the VP7 protein, while highly conserved within serogroups, exhibits sufficient antigenic divergence between AHSV and EEV to allow serogroup-specific immunoassays [14]. This antigenic distinctiveness is critical for differential diagnosis, especially in regions where AHSV and EEV co-circulate and produce overlapping clinical signs [2, 15]. The development of robust serogroup-specific diagnostic tools, such as competitive enzyme-linked immunosorbent assays (ELISAs) and serum neutralization tests (SNTs), has been essential for epidemiological surveillance and for distinguishing EEV infection from other notifiable arboviral diseases of equids [6, 10, 14, 24].

Vector Control and Environmental Management

Because EEV is an obligate vector-borne pathogen transmitted exclusively by hematophagous Culicoides midges (Diptera: Ceratopogonidae), control strategies must prioritize vector management as a cornerstone of disease prevention [1, 2, 12, 16]. The epidemiology of EEV is inextricably linked to the ecology, abundance, and activity of competent Culicoides species, which vary geographically and are profoundly influenced by climatic factors such as temperature, humidity, and precipitation [2, 5, 13]. Mechanistic studies have demonstrated that Culicoides midges serve as biological vectors for EEV, supporting viral replication and transmission, with minimum infection rates (MIR) ranging from 0.2 to 0.4 in surveillance pools collected in South Africa [16]. The identification of EEV RNA in Culicoides pools confirms the role of these midges in the natural transmission cycle and underscores the potential for viral spread into new geographic niches via vector dispersal [16].

Vector control measures include the use of insecticides, insect repellents, and environmental modification to reduce larval breeding sites. Stabling horses during peak vector activity periods (typically dawn and dusk) and the installation of insect-proof screens or mesh on stable openings can significantly reduce exposure to Culicoides bites [11, 18]. In the Netherlands, studies of landing site preferences and diel activity patterns of Culicoides attacking horses have informed evidence-based recommendations for protective housing and the strategic application of insect repellents [18]. However, the efficacy of these measures is directly proportional to the level of compliance and the density of vector populations in the surrounding environment. In endemic regions such as southern Africa and the Middle East, where EEV is enzootic and vector populations are perennial, complete elimination of vector exposure is impractical, necessitating an integrated approach combining vector control with host immunity and movement restrictions [2, 11, 13].

Climate and weather have been demonstrated to exert a profound influence on EEV transmission dynamics. In Israel, a retrospective analysis of EEV seroprevalence and infection rates between 2002 and 2011 revealed that seroprevalence fluctuated significantly across years and climatic regions, with a negative association between infection rate and prior seroprevalence at the farm level [5]. This finding suggests that herd immunity acts as a modulating factor, dampening transmission in populations with high baseline seroprevalence. Critically, the 2008 EEV outbreak in Israel, which confirmed the emergence of the virus outside Africa, was preceded by an exceptionally dry spring, with average precipitation significantly lower than the historical mean [5]. This observation indicates that drought conditions may enhance vector-host contact by concentrating midges around limited water sources, thereby amplifying transmission. Such weather-driven dynamics have important implications for predictive modeling and early warning systems for EEV and other Culicoides-borne diseases.

Biosecurity, Quarantine, and Movement Restrictions

For non-endemic regions or areas at risk of incursion, such as Europe, the implementation of science-based import regulations and pre-movement quarantine is the most effective strategy for preventing the introduction of EEV. A comprehensive risk analysis comparing EEV and AHSV entry probabilities into France demonstrated that EEV is significantly more likely to enter the country than AHSV, primarily through the importation of live infectious horses rather than through infected vectors [11]. This finding is a critical departure from the risk profile of AHSV, which is more likely to be introduced via infected Culicoides transported with livestock. The stochastic spatiotemporal model developed by Faverjon et al. (2017) indicated that the implementation of quarantine before import for horses coming from both European Union (EU) and non-EU countries was the single most effective measure for reducing EEV entry probability [11]. In contrast, vector protection measures applied to all animals (equine and bovine) from low-risk regions were more effective for AHSV [11]. This differential risk profile highlights the necessity for pathogen-specific biosecurity protocols and underscores the importance of cross-border collaboration and harmonization of import standards in accordance with World Organisation for Animal Health (WOAH) guidelines.

Movement restrictions during active outbreaks are essential for containing viral spread, given that EEV is non-contagious and relies entirely on vector-borne transmission [2, 15]. Isolation of clinically affected horses, cessation of horse movements from affected premises, and surveillance of in-contact animals for pyrexia and other clinical signs are standard control measures. However, the high proportion of subclinical infections (up to 41% in foals and likely higher in adult horses) complicates early detection and rapid containment [22]. Serological screening using SNT or ELISA can identify recently exposed animals, but these assays do not distinguish between recent infection and historical exposure, limiting their utility for acute outbreak management [6, 10]. Molecular diagnostics, including real-time reverse transcription polymerase chain reaction (RT-PCR), offer high sensitivity and specificity for detecting viral RNA in whole blood or tissue samples during the viremic phase and are the gold standard for confirming acute EEV infection [3, 4, 23]. The availability of such assays is critical for rapid laboratory confirmation and timely implementation of control measures.

Surveillance, Diagnosis, and Early Warning Systems

Robust surveillance infrastructure is the bedrock of effective EEV control, particularly in regions where the virus is emerging or re-emerging. Historically, EEV was believed to be restricted to southern Africa until 2008, when it was identified in Israel [7, 8]. Retrospective serological analysis subsequently demonstrated that EEV had been circulating in Israel since at least 2001, with seroprevalence rates ranging from 20% to 100% among sampled equine populations during that period [7]. This delayed detection highlights the critical importance of maintaining active surveillance systems for arboviruses with the potential for geographic expansion. The detection of EEV in India in 2008 further underscores the capacity of this virus to invade new ecological niches, facilitated by the widespread presence of competent Culicoides vectors [4]. The spread of EEV from southern Africa to central Africa, the Middle East, and India exemplifies the emerging threat posed by orbiviruses and serves as a sentinel for the possible incursion of more pathogenic viruses, such as AHSV [2, 6, 13].

Differential diagnosis is a particular challenge in EEV-endemic areas because the clinical signs, pyrexia, tachycardia, tachypnoea, icterus, and dyspnea, overlap significantly with those of AHSV, equine influenza, equine herpesvirus, and other arboviral diseases [1, 3, 15]. A prospective study of horses presenting with undefined neurological, febrile, or respiratory signs in South Africa found that 7.3% tested positive for EEV by nested RT-PCR, with 18.9% of positive horses exhibiting icterus and 11.3% exhibiting dyspnea [3]. Notably, neurological signs were inversely associated with EEV infection compared to EEV-negative cases, suggesting that EEV does not typically cause encephalitis despite its name [3]. This is a critical distinction from AHSV, which frequently presents with severe pulmonary or cardiac forms leading to high mortality [12, 15]. The detection of co-infections with West Nile virus, Middelburg virus, or AHSV in 16% of EEV-positive horses further complicates clinical interpretation and underscores the need for multiplex diagnostic panels [3].

The availability of serotype-specific and serogroup-specific serological reagents is essential for both diagnostic accuracy and epidemiological studies. Researchers have developed competitive ELISAs and SNTs capable of differentiating EEV from other orbiviruses, and such tools have been deployed successfully in seroprevalence surveys across Israel, Palestine, Jordan, and Zimbabwe [6, 10]. In Jordan, only 2% of horses tested seropositive for EEV, compared to 58.2% in Israel and 48.5% in Palestine, demonstrating marked geographic heterogeneity in exposure risk [6]. Risk factor analysis in Israel identified farm-level clustering and horse age as significant predictors of seropositivity, with older horses more likely to have been exposed [6]. These data inform targeted surveillance and control efforts, enabling resources to be directed toward high-risk populations and geographic foci.

Vaccination and Prophylaxis

Currently, no commercial vaccine is available for EEV, and the development of an effective vaccine remains a significant unmet need [2, 13]. The lack of a vaccine is attributable to several factors, including the historically perceived mild clinical significance of EEV, the economic constraints associated with vaccine development for a non-WOAH-listed disease, and the antigenic diversity posed by seven distinct serotypes [3, 9]. However, the expanding geographic range of EEV and its potential role as a sentinel for more pathogenic orbiviruses have renewed interest in vaccine development [2, 11, 13]. Lessons learned from the development of vaccines against related orbiviruses, such as BTV and AHSV, provide a valuable framework for designing EEV vaccines [12, 15]. Inactivated whole-virus vaccines, live-attenuated vaccines, and recombinant subunit vaccines have all been explored for BTV and AHSV, with varying degrees of success in terms of safety, efficacy, and duration of immunity [12, 15, 32].

The primary immunological challenge for an EEV vaccine is the need to induce broadly neutralizing antibodies against multiple serotypes while also eliciting robust cell-mediated immunity. The high degree of reassortment observed among EEV serotypes, leading to the emergence of novel strains with mosaic genomes, further complicates vaccine design [3]. A vaccine targeting the highly conserved VP7 inner capsid protein might provide serogroup-level protection but would likely require potent cellular immune responses, as VP7 is not a target of neutralizing antibodies [14, 17]. Alternatively, multivalent vaccines incorporating VP2 proteins from the most epidemiologically relevant serotypes (e.g., serotypes 1, 4, and 6, which are predominant in South Africa) could be employed [3, 9]. The use of reverse genetics, as demonstrated for equine influenza virus vaccine development, could potentially accelerate the generation of high-yield vaccine seed strains for an inactivated or live-attenuated EEV vaccine [32].

Adjuvant technology represents another critical variable in vaccine immunogenicity. Recent advances in equine vaccinology, such as the combination of monophosphoryl lipid A (MPL) and polyinosinic-polycytidylic acid (poly I:C), have been shown to significantly enhance humoral and cellular immune responses in horses, including elevated IgG concentrations, hemagglutination inhibition titers, and memory B- and T-cell responses [30]. While these studies were conducted in the context of equine influenza virus vaccination, the immunological principles are directly translatable to an EEV vaccine platform. The inclusion of potent adjuvants that promote Th1-biased immune responses and induce long-lived plasma cells and memory T cells could overcome the inherent challenges of achieving durable, cross-protective immunity against EEV [30, 31].

In the absence of a licensed vaccine, vector control and movement restrictions remain the primary tools for preventing EEV infection in susceptible equine populations. However, for high-value athletic horses or breeding stock traveling from endemic to non-endemic regions, pre-export quarantine combined with insect-proof housing and antiviral prophylaxis could be considered as risk mitigation strategies. There is no licensed antiviral therapy for EEV; however, broad-spectrum ribonucleoside analogs have demonstrated efficacy against other equine encephalitic alphaviruses, such as Venezuelan equine encephalitis virus (VEEV), in murine models [33]. While EEV is an orbivirus and not an alphavirus, research on the therapeutic activity of compounds like EIDD-1931 (NHC) against alphaviruses establishes a precedent for the development of direct-acting antivirals that could be repurposed or optimized for orbiviral infections [33]. The development of such therapeutics would be a valuable adjunct to vaccination and vector control, particularly for managing outbreaks in naïve populations or for treating clinically affected animals to reduce viremia and subsequent vector-borne transmission.

References

[1] Piketh G, Viljoen A, Eberhardt C. Clinical signs, clinical pathology and outcomes in horses infected naturally with equine encephalosis virus. Equine Veterinary Journal. 2025. DOI: https://doi.org/10.1111/evj.70117

[2] Tirosh-Levy S, Steinman A. Equine Encephalosis Virus. Animals. 2022. DOI: https://doi.org/10.3390/ani12030337

[3] Snyman J, Koekemoer O, Schalkwyk Av, Vuren PJv, Snyman LP, Williams J, et al.. Epidemiology and Genomic Analysis of Equine Encephalosis Virus Detected in Horses with Clinical Signs in South Africa, 2010–2017. Viruses. 2021. DOI: https://doi.org/10.3390/v13030398

[4] Yadav P, Albariño C, Nyayanit DA, Guerrero L, Jenks MH, Sarkale P, et al.. Equine Encephalosis Virus in India, 2008. Emerging Infectious Diseases. 2018. DOI: https://doi.org/10.3201/eid2405.171844

[5] Aharonson-Raz K, Steinman A, Kavkovsky A, Bumbarov V, Berlin D, Lichter-Peled A, et al.. Analysis of the Association of Climate, Weather and Herd Immunity with the Spread of Equine Encephalosis Virus in Horses in Israel. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12424

[6] Tirosh-Levy S, Gelman B, Zivotofsky D, Quraan L, Khinich E, Nasereddin A, et al.. Seroprevalence and risk factor analysis for exposure to equine encephalosis virus in Israel, Palestine and Jordan. Veterinary Medicine and Science. 2017. DOI: https://doi.org/10.1002/vms3.58

[7] Wescott D, Mildenberg Z, Bellaiche M, McGowan S, Grierson S, Choudhury B, et al.. Evidence for the Circulation of Equine Encephalosis Virus in Israel since 2001. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0070532

[8] Aharonson-Raz K, Steinman A, Bumbarov V, Maan S, Maan N, Nomikou K, et al.. Isolation and Phylogenetic Grouping of Equine Encephalosis Virus in Israel. Emerging Infectious Diseases. 2011. DOI: https://doi.org/10.3201/eid1710.110350

[9] Howell PG, Nurton J, Nel D, Lourens CW, Guthrie A. Prevalence of serotype specific antibody to equine encephalosis virus in Thoroughbred yearlings in South Africa (1999-2004).. Onderstepoort Journal of Veterinary Research. 2008. DOI: https://doi.org/10.4102/OJVR.V75I2.14

[10] Gordon S, Bolwell C, Rogers C, Musuka G, Kelly P, Guthrie A, et al.. The sero-prevalence and sero-incidence of African horse sickness and equine encephalosis in selected horse and donkey populations in Zimbabwe. Onderstepoort Journal of Veterinary Research. 2017. DOI: https://doi.org/10.4102/ojvr.v84i1.1445

[11] Faverjon C, Leblond A, Lecollinet S, Bødker R, Koeijer A, Fischer E, et al.. Comparative Risk Analysis of Two Culicoides‐Borne Diseases in Horses: Equine Encephalosis More Likely to Enter France than African Horse Sickness. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12577

[12] Negessu D, Worku T. Review on the Biology of African Horse Sickness Virus and Its Vector. . 2020. DOI: https://doi.org/10.11648/J.IJAST.20200403.11

[13] Davis U, Maclachlan N, Guthrie A. Re-emergence of bluetongue, African horse sickness, and other Orbivirus diseases. Veterinary Research. 2010. DOI: https://doi.org/10.1051/vetres/2010007

[14] Wyngaardt Wv, Mashau C, Wright I, Fehrsen J. Serotype- and serogroup-specific detection of African horsesickness virus using phage displayed chicken scFvs for indirect double antibody sandwich ELISAs. Journal of Veterinary Sciences. 2013. DOI: https://doi.org/10.4142/jvs.2013.14.1.95

[15] K E. Review on African Horse Sickness. Austin Journal of Veterinary Science & Animal Husbandry. 2023. DOI: https://doi.org/10.26420/austinjvetscianimhusb.2023.1123

[16] Snyman J, Venter G, Venter M. An Investigation of Culicoides (Diptera: Ceratopogonidae) as Potential Vectors of Medically and Veterinary Important Arboviruses in South Africa. Viruses. 2021. DOI: https://doi.org/10.3390/v13101978

[17] Ebersohn K, Coetzee P, Snyman L, Swanepoel R, Venter E. Phylogenetic Characterization of the Palyam Serogroup Orbiviruses. Viruses. 2019. DOI: https://doi.org/10.3390/v11050446

[18] Elbers A, Heuvel SVD, Meiswinkel R. Landing sites and diel activity in Culicoides midges attacking Fjord horses in the Netherlands. Journal of Equine Veterinary Science. 2016. DOI: https://doi.org/10.1016/J.JEVS.2016.02.043

[19] Kapdi A, Dhanze H, Sahu A, Singh V, Kumar M, Bhilegaonkar K, et al.. Sero-positivity of Japanese Encephalitis Virus in Equine Population of India Using IgG ELISA: Unraveling the Need for Vaccination.. Journal of Equine Veterinary Science. 2021. DOI: https://doi.org/10.21203/rs.3.rs-804868/v1

[20] Yadav P, Whitmer S, Sarkale P, Ng TFF, Goldsmith C, Nyayanit D, et al.. Characterization of Novel Reoviruses Wad Medani Virus (Orbivirus) and Kundal Virus (Coltivirus) Collected from Hyalomma anatolicum Ticks in India during Surveillance for Crimean Congo Hemorrhagic Fever. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.00106-19

[21] . equine encephalosis virus. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.96114

[22] Grewar J, Thompson P, Lourens CW, Guthrie A. Equine encephalosis in Thoroughbred foals on a South African stud farm. Onderstepoort Journal of Veterinary Research. 2015. DOI: https://doi.org/10.4102/ojvr.v82i1.966

[23] Williams J, Niekerk Sv, Human S, Wilpe Ev, Venter M. Pathology of fatal lineage 1 and 2 West Nile virus infections in horses in South Africa.. Journal of the South African Veterinary Association. 2014. DOI: https://doi.org/10.4102/jsava.v85i1.1105

[24] Rusi RC, García L, Cámara M, Soutullo A. Validation of an indirect in-house ELISA using synthetic peptides to detect antibodies anti-gp90 and gp45 of the Equine Infectious Anemia Virus (EIAV).. Equine Veterinary Journal. 2022. DOI: https://doi.org/10.1111/evj.13555

[25] Costa VMD, Cursino AE, Luiz APM, Braz GF, Cavalcante PH, Souza CEA, et al.. Equine Infectious Anemia Virus (EIAV): Evidence of Circulation in Donkeys from the Brazilian Northeast Region.. Journal of Equine Veterinary Science. 2021. DOI: https://doi.org/10.1016/j.jevs.2021.103795

[26] Guzmán-Terán C, Calderón-Rangel A, Rodríguez-Morales A, Mattar S. Venezuelan equine encephalitis virus: the problem is not over for tropical America. Annals of Clinical Microbiology and Antimicrobials. 2020. DOI: https://doi.org/10.1186/s12941-020-00360-4

[27] Morens D, Folkers G, Fauci A. Eastern Equine Encephalitis Virus - Another Emergent Arbovirus in the United States.. New England Journal of Medicine. 2019. DOI: https://doi.org/10.1097/INF.0000000000002560

[28] Bannai H, Takahashi Y, Ohmura H, Ebisuda Y, Mukai K, Kambayashi Y, et al.. Decreased Virus-Neutralizing Antibodies Against Equine Herpesvirus type 1 In Nasal Secretions of Horses After 12-hour Transportation.. Journal of Equine Veterinary Science. 2021. DOI: https://doi.org/10.1016/j.jevs.2021.103665

[29] Fortier C, El-Hage C, Hue E, Sutton G, Pitel C, Jeffers K, et al.. Hepatitis viruses: prevalence of equine parvovirus‐hepatitis virus and equine hepacivirus in France and Australia. Equine Veterinary Journal. 2021. DOI: https://doi.org/10.1111/evj.103_13495

[30] Lee D, Eun-Bee L, Jong-Pil S, Eun-Ju K. Adjuvant combination enhances immune response of equine influenza virus vaccine in horses.. Equine Veterinary Journal. 2025. DOI: https://doi.org/10.1111/evj.70090

[31] Oladunni FS, Oseni S, Martínez-Sobrido L, Chambers T. Equine Influenza Virus and Vaccines. Viruses. 2021. DOI: https://doi.org/10.3390/v13081657

[32] Ohta M, Bannai H, Kambayashi Y, Tamura N, Tsujimura K, Yamayoshi S, et al.. Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine.. Equine Veterinary Journal. 2021. DOI: https://doi.org/10.1111/evj.13431

[33] Painter G, Bowen R, Bluemling GR, Debergh J, Edpuganti V, Gruddanti PR, et al.. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection.. Antiviral Research. 2019. DOI: https://doi.org/10.1016/j.antiviral.2019.104597